Disc Medicine to Launch Trial for Iron Overload Treatment in Sickle Cell Disease
Disc Medicine is planning to launch a clinical trial by the end of the year to test DISC-3405, its treatment candidate for iron overload, in people with sickle cell disease (SCD).
Iron overload is a common problem in SCD due to frequent blood transfusions.
“We’re … excited about the progress across our iron homeostasis [balance] portfolio, DISC-0974 and DISC-3405, as these programs will be important drivers of Disc’s future growth,”
said John Quisel, PhD, Disc’s CEO and president. He also stated that the company plans to initiate a Phase 1b trial of DISC-3405 in sickle cell disease by year end.
Author's summary: Disc Medicine plans to test iron overload treatment.
More News
- The Casandra Cascade: Industrialisation Of Fear - FNArena.com
- Pompano Beach man accused of leaving 2 dogs in cages on driveway with no food for days - WSVN 7News | Miami News, Weather, Sports | Fort Lauderdale
- Everett versus Cascade football | Snohomish County Tribune
- Historic Win for Victims: High Court Okays Safe Abortions for Rape Survivors - Malawi Nyasa Times - News from Malawi about Malawi
- Residents worry that more controls needed at Andy’s Place low-barrier housing apartments | Snohomish County Tribune
- Andreas Martin takes over leadership of Autentic Studios
- Rudi's View: Identifying Quality Opportunities - FNArena.com
- Identifying “Invisible” Premium Customers Within Retail Banking Segments
- Africa: Saraki Calls for African Renaissance, Urges End to Dependency At Nairobi Forum
- The Coming Dementia Crisis—and the Cost of Doing Nothing